QUARTERLY REPORT

Pursuant to Rule 15c2-(11)(a)(5)

For

INOLIFE TECHNOLOGIES, INC.

For the Three Months Ended June 30, 2015

Dated: April 6, 2016

All information contained in this Information and Disclosure Statement has been compiled to fulfill the disclosure requirements of Rule 15c2-11 (a)(5) promulgated under the Securities and Exchange Act of 1934, as amended. The enumerated captions contained herein correspond to the sequential format as set forth in the rule.

INOLIFE TECHNOLOGIES, INC.

Table of Contents

Item 1.	The exact name of the Issuer and its predecessors	3
Item 2.	Address of the Issuer's principal executive offices	3
Item 3.	Security Information	3
Item 4.	Issuance History	4
Item 5.	Financial Statements	5
	Unaudited Balance Sheet as of June 30, 2015	
	Unaudited Statement of Operations for the three months ended June 30, 2015 and 2014	
	Unaudited Statement of Cash Flows for the three months ended June 30, 2015 and 2014	
	Notes to Consolidated Financial Statements	
Item 6.	Issuer's Business, Products, and Services	13
Item 7.	Issuer's Facilities	14
Item 8.	Officers, Directors, and Control Persons	14
Item 9.	Third Party Providers	15
Item 10.	Issuer Certification	15

INOLIFE TECHNOLOGIES INC.
QUARTERLY REPORT

All information contained in this Quarterly Report has been compiled to fulfill the disclosure requirements of Rule 15c2-11 (a)(5) promulgated under the Securities and Exchange Act of 1934, as amended. The enumerated captions contained herein correspond to the sequential format as set forth in the rule.

No dealer, salesman or any other person has been authorized to give any information or to make any representations not contained herein in connection with the Issuer. Any representations not contained herein must not be relied upon as having been made or authorized by the Issuer.

Delivery of this information does not imply that the information contained herein is correct as of any time subsequent to the date of this Issuers Quarterly Report.

ITEM 1. THE EXACT NAME OF THE ISSUER AND ITS PREDECESSORS

The exact name of the Issuer is:

INOLIFE TECHNOLOGIES Inc. (hereinafter referred to as "INOLIFE TECHNOLOGIES", "INOL", "Issuer" or "Company").

Predecessor entities since inception and dates of name changes:

- InoLife Technologies, Inc. since 1-2010
- Formerly=NexxNow, Inc. until 1-2010
- Formerly=Centale, Inc. until 6-2008
- Acquired=4-25-08 the outstanding capital stock of NexxNow China, Inc. (DE) for 43 million common shs of the company.

ITEM 2. ADDRESS OF THE ISSUER'S PRINCIPAL EXECUTIVE OFFICES

Company Headquarters:

- Address: 300 Spectrum Center Drive
  Suite 400
  Irvine, CA 92618

- Website: www.inolifetech.com
- Phone: 1-866-834-3777
  Email: info@inolife.net

Investor Relations Firm:
None

ITEM 3. SECURITY INFORMATION

Trading symbol
The Company's trading symbol is INOL.

The Company's CUSIP
The Company's CUSIP is 45776Y 300

Par or Stated Value:
The Company's Common Stock has $0.00001 par value.

Shares Authorized and Outstanding

As of the date of this Report, the Issuer has two classes of securities; Common Stock and Preferred Stock.

The Company is authorized is five billion (5,000,000,000) at par value of $0.00001 with 1,524,897,616 are issued and outstanding as of March 31, 2016.

The Company has one hundred million (100,000,000) shares of Preferred Stock authorized at par value of $0.00001 with 213,322 issued and outstanding, respectively issued and outstanding as of March 31, 2016.

Transfer Agent

John Ahearn
Manhattan Transfer Registrar Company
531 Cardens Court
Erie, Co 80516
Phone:(631) 928-7655
Fax: (631) 209-8143 Fax
Toll Free: (877) 645-8691
Email: jahearn@mtrco.com
Web: www.mtrco.com<http://www.mtrco.com/>

*The Company's transfer agent is registered under the Exchange Act.

Restrictions on the transfer of any security:
None

Describe any trading suspension orders issued by the SEC in the past 12 months: None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

The Company is in the process of completing a business combination with a company who manufactures and distributes needless injectors. Pursuant to the terms of the combination, the Company will need to complete a thirty thousand (30,000) to one (1) stock reverse. Along with other conditions as defined in the agreement. The reverse was approved by the board of directors and majority of shareholders and has been presented for approval by the Financial Industry Regulatory Authority, Inc. ("FINRA").

ITEM 4. ISSUANCE HISTORY

Events by the Issuer Resulting in Changes in Total Outstanding Shares for the Past Two Fiscal Years:

To the best knowledge of the present management of the Company, the list identified below identifies all events, in chronological order, that resulted in changes in total shares outstanding by the Company (1) within the two-year period ending on the last day of the Company's most recent fiscal year and (2) since the last day of the Company's most recent fiscal year.

During the quarter ended June 30, 2015, the Company issued an aggregate of 0 shares of restricted common stock to it's shareholders.

ITEM 5. FINANCIAL STATEMENTS

Unaudited financial statements for the quarter ended June 30, 2015, are included herein. The numbers contained in this filing are exclusively the accounting numbers for InoLife Technologies, Inc. The financial statements requested pursuant to this item have been prepared in accordance with US GAAP by management and persons with sufficient financial skills.

For the Three Months Ending June 30, 2015

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

INOLIFE TECHNOLOGIES, INC.
Consolidated Balance Sheets

	June 30, 2015	June 30, 2014
ASSETS		
Current Assets		
Cash and cash equivalents	$ 103	103
Prepaid Expenses	-	-
Total Current Assets	$ 103	103
TOTAL ASSETS	$ 103	103
LIABILITIES AND STOCKHOLDERS' DEFICIT		
Current Liabilities		
Accounts payable	$ 436,215	870,174
Accrued management fees, related party	948,771	946,924
Accrued consulting fees	77,700	65,200
Accrued employer taxes	101,734	101,734
Accrued interest	199,830	199,830
Convertible notes payable	550,829	550,829
Derivative Liability	228,000	228,000
Note payable, related party	78,959	78,959
Total Current Liabilities	2,622,038	3,041,650
TOTAL LIABILITIES	2,622,038	3,041,650
Commitments and Contingencies		
Stockholders' Deficit		
Preferred stock: 100,000,000 authorized; $0.00001 par value		
132,774 and 213,322 issued and outstanding, respectively	52	52
Preferred Stock - Series C, par value $0.01 per share,		
572 and 572 issued and outstanding, respectively	6	6
Common stock: 5,000,000,000 authorized; $0.00001 par value		
903,929,944 and 40,040,492 issued and outstanding, respectively	2,235	2,235
Additional paid in capital	8,135,810	7,639,789
Accumulated deficit	(11,082,103)	(10,683,629)
Total Stockholders' Deficit	(2,946,293)	(3,041,547)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 103	3

The accompanying notes are an integral part of these condensed consolidated financial statements.

INOLIFE TECHNOLOGIES, INC.
Consolidated Statements of Operations

	Three months ended June 30,	
	2015	**2014 (Restated)**
Revenues	$ -	$ -
Operating Expenses		
Professional fees	12.500	199,250
Management expenses	77,500	283,800
Selling, general and administrative expense	15,393	6,222
Total operating expenses	105,393	489,272
Net loss from operations	(105,393)	(489,272)
Other income (expense)		
Interest expense	(9,464)	(9,465)
Gain on debt forgiveness	-	-
Other Income	0	0
Change in fair value of derivative	-	-
	(9,464)	(9,465)
Loss before provision for taxes	(114,857)	(498,736)
Provision for income taxes	-	-
Net loss	$ (114,857)	$ (498,736)
Basic and diluted loss per share	$ (0.00)	$ (0.00)
Weighted average number of shares outstanding	903,929,944	158,367,451

The accompanying notes are an integral part of these condensed consolidated financial statements.

INOLIFE Technologies, Inc.
Consolidated Statements of Cash Flows

	3 months ended June 30, 2015	3 months ended June 30, 2014 (restated)
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net Loss	$ (105,393)	$ (498,736)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:		
Change in fair value of derivative	-	-
Common stock issued in exchange for services	550,325	310,548
Changes in assets and liabilities:		
(Increase) Decrease in prepaid expense	-	-
Increase (Decrease) in accounts payable	82,402	82,402
Increase(Decrease) in accrued liabilities	(465,715)	(165,715)
Increase(Decrease) in Management fess	(156,836)	262,136
Increase(Decrease) in note payable to related parties	-	-
Increase(Decrease) in accrued interest	9,465	9,465
Net Cash Used in Operating Activities	$ 100	$ 100
CASH FLOWS PROVIDED BY (USED FOR) INVESTING ACTIVITIES:		
Net Cash Used in Investing Activities	-	-
CASH FLOWS PROVIDED BY (USED FOR) FINANCING ACTIVITIES:		
Net Cash Provided by (Used for) Financing Activities	-	-
NET INCREASE (DECREASE) IN CASH	100	100
CASH AT BEGINNING OF PERIOD	3	3
CASH AT END OF PERIOD	$ 103	$ 103
SUPPLEMENTAL CASH FLOW INFORMATION:		
Cash Paid for interest	-	-
Cash Paid for taxes	-	-
Common Stock issued for services	550,235	310,548
Common Stock issued upon conversion	-	-

The accompanying notes are an integral part of these condensed consolidated financial statements.

INOLIFE TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
June 30, 2015
(UNAUDITED)

NOTE 1 – THE COMPANY

HISTORY

InoLife Technologies, Inc. (the "Company") was incorporated under the laws of the State of New York on November 12, 1998 as Safe Harbour Health Care Properties, Ltd. During 1999, the Company ceased its operations. The Company remained dormant until 2004, when one of the Company's shareholders purchased a controlling interest. In February 2004, the Company began its development stage as an internet based marketing company. The Company, as of December 2007 discontinued its internet marketing due to difficulties with service providers and subsequent cancellations by customers.

In August 2009, Gary Berthold purchased 35,013,540 shares of InoLife Technologies, Inc. representing a majority of the outstanding shares. In connection with the purchase, all of the directors and officers of the Company resigned from their positions, after first appointing Berthold as a director.

Effective September 17, 2009, the Board of Directors of the Company authorized the execution of a share exchange agreement (the "Share Exchange Agreement") with InoVet, Ltd., a Delaware corporation ("InoVet") and the shareholders of InoVet (the "InoVet Shareholders"). In accordance with the terms and provisions of the Share Exchange Agreement, the Company agreed to: (i) acquire all of the issued and outstanding shares of common stock of InoVet from the InoVet Shareholders; and (ii) issue an aggregate of 10,000,000 shares of its restricted common stock to the InoVet Shareholders.

On July 7, 2011, the Company acquired 100% of the issued and outstanding shares of Stemtide Inc. in exchange for 50,000,000 shares of common stock of the Company, the assumption of certain outstanding liabilities, and contingent residual payments of 10% of the gross profits derived from the sale of Stemtide Inc.'s Age-Reversing Products. The principal asset of Stemtide Inc. that was acquired was the manufacturing and marketing rights to the Stemtide Age-Reversing Products, throughout the United States, licensed from an affiliate of the principal shareholders of InoLife.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Unaudited Interim Consolidated Financial Statements:

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States ("GAAP") for complete consolidated financial statements. In the opinion of management, all adjustments (consisting only of normal recurring accruals, unless otherwise indicated) considered necessary for a fair presentation of the interim financial data have been included. Operating results for the three and nine months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the fiscal year ending March 31, 2015. Events occurring subsequent to June 30, 2015 have been evaluated for potential recognition or disclosure in the unaudited consolidated financial statements for the three and nine months ended June 30, 2015.

The accompanying unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2014, which were filed with the Securities and Exchange Commission (the "SEC") on July 15, 2014.

The condensed consolidated balance sheet at March 31, 2014 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by generally accepted accounting principles in the U.S. for complete financial statements.

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and

expenses during the reporting period. Actual results could differ from those estimates.

Management believes that all adjustments necessary for a fair statement of the results of the three months ended June 30, 2015 have been made.

Significant Accounting Policies:

Basis of Presentation:

The Company prepares its consolidated financial statements on the accrual basis of accounting. All intercompany balances and transactions are eliminated.

Cash and Cash Equivalents:

All highly liquid investments with original maturities of three months or less are included in cash and cash equivalents. All deposits are maintained in FDIC insured depository accounts in local financial institutions and balances are insured up to $250,000.

Earnings Per Share:

Basic earnings (loss) per share are computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per share include the effects of any outstanding options, warrants and other potentially dilutive securities. Basic and diluted earnings per share ("EPS") are based on weighted-average common shares and exclude shares that would have an anti-dilutive effect. The Company did not consider any potential common shares in the computation of diluted EPS as of June 30, 2015 and 2013, due to the loss from operations, as they would have an anti-dilutive effect on EPS.

Share Based Payments:

The Company accounts for share based payments using a fair value based method whereby compensation cost is measured at the grant date based on the value of the services received and is recognized over the service period. The Company uses the Black-Scholes pricing model to calculate the fair value of options and warrants issued. In calculating this fair value, there are certain assumptions used such as the expected life of the option, risk-free interest rate, dividend yield, volatility and forfeiture rate. The use of a different estimate for any one of these components could have a material impact on the amount of calculated compensation expense.

Segment Reporting

The Company has determined it has only one operating segment as of the periods presented.

Income Taxes

The Company accounts for income taxes under ASC 740 *Income Taxes*. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. The Company has had significant operating losses and a valuation allowance is recorded for the entire amount of the deferred tax assets, resulting in no deferred tax assets or liabilities recognized as of June 30, 2015.

The Company accounts for uncertain tax positions according to the provisions of ASC 740. ASC 740 contains a two-step approach for recognizing and measuring uncertain tax positions. Tax positions are evaluated for recognition by determining if the weight of available evidence indicates that it is probable that the position will be sustained on audit, including resolution of related appeals or litigation. Tax benefits are then measured as the largest amount which is more than 50% likely of being realized upon ultimate settlement. The Company considers many factors when evaluating and estimating tax positions and tax benefits, which may require periodic adjustments and which may not accurately anticipate actual outcomes.

The company's open tax periods are 2009 through 2013.

Recently Issued Accounting Pronouncements:

On December 31, 2014 the FASB issued ASU No. 2014-10, *Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation*. The amendments in this ASU remove all incremental financial reporting requirements from U.S. GAAP for development stage entities. The Company has elected to early adopt this guidance, and therefore is no longer presenting the financial statements in accordance with ASU 915, with inception to date disclosures.

The Company is evaluating how to apply ASU 605, *Revenues from Contracts with Customers,* before its effective date, however, as the Company does not yet have revenue to recognize, it will not have an impact on current results of operations, financial position or cash flow.

NOTE 3 – CONVERTIBLE NOTES PAYABLE

Convertible notes payable consist of the following at June 30, 2015:

	Due Date	Interest	June 30, 2015	June 30, 2014
Just Marketing	Demand	10%	40,000	-
New Opportunity Business Solutions	Demand	10%	-	27,500
			40,000	27,500
Debt Discount			-	10,412
			40,000	17,500

The Company has evaluated their convertible notes for embedded derivative features and has determined that in several of the notes a derivative liability is necessary to recognize. These notes contain a conversion feature which includes a "reset" provision, whereby the conversion rate would be reset should there be future equity sales at a price less than the conversion rate in effect at the time. Therefore, the conversion feature is required to be bifurcated and accounted for under derivative accounting, and remeasured each period end, with any changes in the fair value of the derivative to be recognized in income. During the three and nine months ended June 30, 2015 there was no change in fair value of the derivative liability. During the nine months ended December 31, 2013 there was a reduction in the derivative liability of $137,344 due to the reduction of the related notes principal balances, which was recognized as a separate line item on the accompanying Statement of Operations. The fair value of the derivative liability as of both June 30, 2015 and March 31, 2014, has been determined to be $228,000. Derivative liabilities were valued using a probability based weighted-average Black-Scholes-Merton valuation with the following assumptions:
At June 30, 2015 and March 31, 2014 the accrued interest on all notes is approximately $20,000 and $31,500, respectively.

NOTE 4 – RELATED PARTY TRANSACTIONS

On June 2, 2014, the Company issued 5,000,000 shares of its Series B Preferred Stock ("PS") to the CEO, who is also one of the founders and majority shareholders of the Company. The PS is convertible into common stock six months after issuance, at a mathematical calculation, which as of issuance represented a 1 PS to 250,000 common stock conversion ratio. The PS has been recognized as a distribution of capital, which resulted in no impact on additional paid in capital.

NOTE 5 – COMMON AND PREFERRED STOCK

Please see Note 4 for a discussion of Preferred Stock issued to related parties.

The shares of the Company's common stock issued during the three month period ended June 30, 2015 as described below qualified for an exemption under Section 4(a)(2) of the Securities Act, as amended (the "Securities Act") because the issuance of shares by the Company did not involve a public offering. The offering was not a "public offering" as defined in Section 4(a)(2) of the Securities Act due to the insubstantial number of persons involved in each

of the issuances, size of the offering, manner of the offering and number of shares offered and the pre-existing relationship with the Company and the purchaser. Based on an analysis of the above factors, the Company has met the requirements to qualify for exemption under Section 4(a)(2) of the Securities Act for the securities transaction described below.

On November 3, 2014, the Company issued to two investors an aggregate of 48,250,000 shares of common stock upon the investor's conversion of $4,285 of principal of convertible notes.

On December 9, 2014, the Company issued to an investor 24,540,000 shares of common stock upon the investor's conversion of $1,227 of principal of a convertible note.

On December 24, 2014, the Company issued 55,000,000 shares of common stock to an investor upon the investor's conversion of $550 of principal of a convertible note.

On December 30, 2014, the Company issued 35,000,000 shares of restricted common stock and 40,000 shares of Series B Preferred Stock to the Company's Director of SEC Compliance and Regulations. The Company took a charge of $5,400 for these stock issuances.

NOTE 6 – FINANCIAL CONDITION AND GOING CONCERN

The Company has minimal operations and has negative working capital at June 30, 2015. Due to the limited operating history and limited operations, the Company will require additional working capital to survive. The Company is currently working on completing and going live with their website, through which they will market their products. The first products to be marketed will be the Stemtide Anti-Aging Products Line. Management expects revenue on these products to begin being recognized during the first quarter of fiscal 2015. If the funds the Company has are not sufficient, it will also consider bank loans and additional shareholder loans. There are no assurances that the Company will be able to obtain any of these. No assurance can be given that additional financing will be available, or will be available, will be on terms acceptable to the Company. If adequate working capital cannot be generated, the Company may not be able to continue its operations.

These conditions raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might be necessary should the Company be able to continue as a going concern.

NOTE 7– SUBSEQUENT EVENTS

On February 1, 2016, InoLife Technologies, Inc., a New York corporation (the "Registrant" or "Company"), entered into a Definitive Merger Agreement ("Agreement") with 8687544 Canada, Inc. ("8687544"), pursuant to which the Registrant has agreed to issue 8687544 thirty million shares of common stock, after a thirty thousand to one (30,000 to 1) reverse split of the Registrant's existing issued and outstanding shares, in consideration for 8687544's rights title and interest to a needle free injector system. Including the following rights and assets:

A. Design, Specifications and Intellectual Properties of the Needle Free Injector System 505 (for injection of 0.5ml, both reusable and disposable), and One30 (a disposable injection of 0.3).

B. Regulatory Approvals for the Needle Free Injector (FDA, Health Canada and European). FDA Version Number – M GBA EN FR R01 1209SFR

C. Any and all marketing materials, presentation, clinical trials, research. Including brand name use.

D. Any and All Global Rights and Ownership to the Needle Free Injector System and technology referred to as Injex and or its equivalent Generic IP, including but not limited to its designs, its technical know-how, and trade secrets.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements: No Assurances Intended

In addition to historical information, this report contains forward-looking statements, which are generally identifiable by use of the words" believes," "expects," "intends," "anticipates," "plans to," "estimates," ''projects," or similar expressions. These forward-looking statements represent Management's belief as to the future of the Company. Whether those beliefs become reality will depend on many factors that are not under management's control. Many risks and uncertainties exist that could cause actual results to differ materially from those reflected in these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements.

Results of Operations

Due to our continued lack of funds, our operations are very limited. As a result, we realized no revenue during the period ended June 30, 2015. The Company is expecting to begin recognizing revenue early in the next fiscal year as their website is expected to go live during the quarter ended March 31, 2015.

The largest expense during the three and nine months ended June 30, 2015 and 2013 was for management fees. The majority of these fees were incurred in the three months ended June 30, 2014. Included in the management fees, the officers and directors of the Company received approximately $283,750 in issuances of Preferred and Common shares, with an additional $104,250 issued to attorneys. $77,500 was accrued each period in accordance with the employment agreement for the CEO. Another $27,900 and $145,800, respectively, was incurred during the three and nine months ended June 30, 2015 for accounting and consulting fees related to the annual financial statements included in the Form 10K filed and other SEC filings. $62,900 of these accrued fees were paid during the three months ended June 30, 2015 through the issuance of the Company’s common shares.

The additional management fees expense for the period ending December 31, 2013 as compared to June 30, 2015, was for shares issued to consultants as signing bonuses for agreeing to serve in executive and director positions with the Company going forward, as well as increased legal fees. The common stock was valued at the markets closing price on the day of issuance, which was $0.22 per share on June 4, 2013 as compared to $0.0015 on June 2, 2014.

We realized a net loss of approximately $125,000 and $740,000 for the three and nine months ended June 30, 2015, compared to net loss of approximately $171,000.00 and $2,321,000 for the three and nine months ended December 31, 2014.

Liquidity and Capital Resources

At June 30, 2015 we have a cash position of approximately $100. Since we initiated our business operations in 2009, our operations have been funded primarily by the private sale of equity and debt to investors. As a result, through June 30, 2015, we had used all of our funds for our operations. However, as noted above, the Company is expecting to begin selling their products and collecting revenue in the next three months.

The Company has issued various convertible debentures to accredited investors with interest rates ranging from 8% to 20%. The investors can convert the principal and accrued but unpaid interest of the debentures into shares of the Company's common stock. As of June 30, 2015, there were approximately $551,000 of convertible notes payables.

We continue to actively seek investment capital. At the present time, however, we have had limited commitments from funders to provide us any additional funds.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably expected to have a current or future effect on our financial condition or results of operations.

Impact of Accounting Pronouncements

On June 10, 2014 the FASB issued ASU No. 2014-10, *Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810,*

Consolidation. The amendments in this ASU remove all incremental financial reporting requirements from U.S. GAAP for development stage entities. The Company has elected to early adopt this guidance, and therefore is no longer presenting the financial statements in accordance with ASU 915, with inception to date disclosures.

The Company is evaluating how to apply ASU 605, *Revenues from Contracts with Customers,* before its effective date, however, as the Company does not yet have revenue to recognize, it will not have an impact on current results of operations, financial position or cash flow.

Plan of Operation

lnoLife Technologies, Inc. is organized to develop and market Skin Care and DNA Testing products within the US. The Company's mission has not been a success. On May 4, 2015, InoLife Technologies, Inc., a New York corporation (the "Registrant" or "Company"), entered into a binding letter of intent ("LOI") with Sports Shop Network LLC ("SSN") and Wideshot Productions/Media LLC ("Wideshot"), pursuant to which the Registrant has agreed to purchase from SSN 20,000 television minutes that may be used for the placement of short or long form insertions (advertising) on selected national cable networks, regional cable networks, cable carriers, satellite carriers and local wired full power television stations (the "Media Minutes"). SSN acquired the right to use the Media Minutes from Wideshot. The purchase price for the Media Minutes is $100,000 of which $25,000 shall be paid within 45 days after the execution of a definitive asset purchase agreement for the purchase of the Media Minutes. After the Registrant has paid the purchase price in full, the Registrant is required to secure additional funding over a six (6) month period which will be used to put the Media Minutes into production.

The acquisition of the Media Minutes is subject to the Company's satisfactory due diligence review of the Media Minutes and SSN. The Company has the right to terminate the LOI if its due diligence of the Media Minutes or SSN is unsatisfactory.

lnoLife is committed to our shareholders to increase the fundamental value of the Company's stock. The key to the success of each of these divisions is investment and key personnel. Management is currently in discussions with interested investment groups to help fund the Company's development and marketing initiatives. lnoLife is already in the process of bringing on board the right management talent to make this all happen.

Our Independent Auditors have expressed substantial doubt about our ability to continue as a going concern.

As we don't have enough cash on hand to pay our expenses for the next 12 months of operations, our independent auditors have included a "going concern" qualification in their audit report. The Company will have to continue to raise funds to continue to operate.

We require additional financing and our inability to raise additional capital on acceptable terms in the future may have a material adverse effect on our business and financial condition.

We do not have sufficient operating capital to fund our operations for the next 12 months and must raise that capital through loans and/or sales of our common stock. There is no guarantee that we will be able to do so. Failure to do so could cause us to have to cut operations and delay development and introduction of our products.

Because we have a limited operating history to evaluate our company and are implementing a new business model, the likelihood of our success must be considered in light of the problems, expenses, difficulties, complications and delays frequently encountered by a new company.

Since we have a limited operating history we cannot assure you that our business will generate revenues or be profitable. Early stage companies often are unsuccessful and encounter unanticipated expenses and difficulties, investors should consider this risk in determining whether to purchase or sell our common stock.

Our current management holds significant control over our common stock and they may be able to control our Company indefinitely.

Our management has significant control over our voting stock that may make it difficult to complete some corporate transactions without their support and may prevent a change in control. As of June 30, 2015, our directors and executive officers as a whole, beneficially own approximately 197,000,000 shares of our common stock, and all of our Preferred Stock. The above-described significant stockholders will have considerable influence over the outcome of all matters submitted to our stockholders for approval, including the election of directors. In addition, this ownership

could discourage the acquisition of our common stock by potential investors and could have an anti-takeover effect, possibly depressing the trading price of our common stock.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not applicable for small business issuers

Item 4. Controls and Procedures.

Management's Conclusions Regarding Effectiveness of Disclosure Controls and Procedures.

The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting. The Company's internal control over financial reporting is a process designed under the supervision of the Company's Chief Executive Officer and Chief Financial Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company's financial statements for external purposes in accordance with U.S. generally accepted accounting principles.

With respect to the period ending June 30, 2015, under the supervision and with the participation of our management, we conducted an evaluation of the effectiveness of the design and operations of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934.

Based upon our evaluation regarding the period ending June 30, 2015, the Company's management, including its Chief Executive Officer and Chief Financial Officer, has concluded that its disclosure controls and procedures were not effective due to the Company's limited internal resources and lack of ability to have multiple levels of transaction review. Through the use of external consultants and the review process, management believes that the financial statements and other information presented herewith are materially correct.

The Company's disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives. However, the Company's management, including its Chief Executive Officer and Chief Financial Officer, does not expect that its disclosure controls and procedures will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefit of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected.

Changes in Internal Controls.

There have been no changes in the Company's internal control over financial reporting during the period ended June 30, 2015 that have materially affected, or are reasonably likely to materially affect, the Company's internal controls over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

Inolife Technologies, Inc. v. Sharon P. Berthold, 14 CVS 3156-Forsyth County, North Carolina:

This is an action against a former officer of the Company. Counsel for Inolife believes that the litigation has no material detrimental effect to the Company’s financial situation.

The Company is currently not involved in any other litigation that we believe could have a material adverse effect on our financial condition or results of operations.

To the best of our knowledge, except as set forth herein, none of the directors or director designees to our knowledge has been convicted in a criminal proceeding, excluding traffic violations or similar misdemeanors, or has been a party to any judicial or administrative proceeding during the past five years that resulted in a judgment decree or final order enjoining the person from future violations of, or prohibiting activities subject to, federal or state securities laws, or

finding of any violation of federal or state securities laws, except for matters that were dismissed without sanction or settlement.

Item lA. Risk Factors.

Not required for smaller reporting companies.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

The shares of the Company's common stock issued during the three month period ended June 30, 2015 as described below qualified for an exemption under Section 4(a)(2) of the Securities Act, as amended (the "Securities Act") because the issuance of shares by the Company did not involve a public offering. The offering was not a "public offering" as defined in Section 4(a)(2) of the Securities Act due to the insubstantial number of persons involved in each of the issuances, size of the offering, manner of the offering and number of shares offered and the pre-existing relationship with the Company and the purchaser. Based on an analysis of the above factors, the Company has met the requirements to qualify for exemption under Section 4(a)(2) of the Securities Act for the securities transaction described below.

On November 3, 2014, the Company issued to two investors an aggregate of 48,250,000 shares of common stock upon the investor's conversion of $4,285 of principal of convertible notes.

On December 9, 2014, the Company issued to an investor 24,540,000 shares of common stock upon the investor's conversion of $1,227 of principal of a convertible note.

On December 24, 2014, the Company issued 55,000,000 shares of common stock to an investor upon the investor's conversion of $550 of principal of a convertible note.

On December 30, 2014, the Company issued 35,000,000 shares of restricted common stock and 40,000 shares of Series B Preferred Stock to the Company's Director of SEC Compliance and Regulations. The Company took a charge of $5,4000 for these stock issuances.

Item 3. Defaults upon Senior Securities.

There has been no default in the payment of principal, interest, sinking or purchase fund installment, or any other material default not cured within 30 days, with respect to any indebtedness of the Company.

Item 4. Mine Safety Disclosure.

Not applicable

Item 5. Other Information.

There is no other information required to be disclosed under this item which was not previously disclosed.

ITEM 6. OFFICERS, DIRECTORS, AND CONTROL PERSONS

A. Officers, Directors, and Control Persons as of the date of this Quarterly Report's publication with OTC Markets

Name	Title
Gary Berthold 6040A Six Forks Rd #135 Raleigh, NC 27609	President and Chief Executive Officer, Secretary, Treasurer, Chief Financial Officer, and Director

B. Involvement in Certain Legal Proceedings

None of the officers, directors, promoters or control persons of the Issuer have been involved in the past five (5) years in any of the following:

(1) A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and minor offenses);
(2) The entry of an order, judgment, or decree, not subsequently reverse, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities or bank activities;
(3) A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or
(4) The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

C. Beneficial Shareholders

The name, address and shareholdings of all persons beneficially owning more than ten percent of any class of the Company's equity securities or officers and directors of the Company are:

Name	Common Directly Owned[(1)]	Percent Ownership[(2)]
Gary Berthold 6040A Six Forks Rd #135 Raleigh, NC 27609	132,000,604	8%

(1) Share totals reflect all common shares directly owned as of the date of this report's publication with OTC markets.
(2) As of the date of this report's publication there we1,524,897,616 shares of common stock issued and outstanding.

ITEM 9. THIRD PARTY PROVIDERS

Counsel
Randall J. Lanham, Esq.
Lanham & Lanham, LLC
28562 Oso Parkway, Unit D
Rancho Santa Margarita, CA 92688

Accountant or Auditor

None. These financials were prepared internally by management.

ITEM 10. SUBSEQUENT EVENTS

On February 1, 2016, InoLife Technologies, Inc., a New York corporation (the "Registrant" or "Company"), entered into a Definitive Merger Agreement ("Agreement") with 8687544 Canada, Inc. ("8687544"), pursuant to which the Registrant has agreed to issue 8687544 thirty million shares of common stock, after a thirty thousand to one (30,000 to 1) reverse split of the Registrant's existing issued and outstanding shares, in consideration for 8687544's rights title and interest to a needle free injector system. Including the following rights and assets:

A. Design, Specifications and Intellectual Properties of the Needle Free Injector System 505 (for injection of 0.5ml, both reusable and disposable), and One30 (a disposable injection of 0.3).

B. Regulatory Approvals for the Needle Free Injector (FDA, Health Canada and European). FDA Version Number – M GBA EN FR R01 1209SFR

C. Any and all marketing materials, presentation, clinical trials, research. Including brand name use.

D. Any and All Global Rights and Ownership to the Needle Free Injector System and technology referred to as Injex and or its equivalent Generic IP, including but not limited to its designs, its technical know-how, and trade secrets.

ITEM 11. ISSUER CERTIFICATION

I, Dr. John Oda, Chief Executive Officer certify that:

1. I have reviewed this quarterly disclosure statement of INOLIFE TECHNOLOGIES, Inc.;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations, and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: April 6, 2016
Signature: /s/ *Dr. John Oda*
Title: Chief Executive Officer